Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002169 · ClinicalTrials.gov registry record · Phase 2
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
A Phase 2 study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Study locations
NCT00002169 is a Phase 2 study of HIV Infections and Cytomegalovirus Retinitis that has completed, run by Agouron Pharmaceuticals. The trial reports 8 study locations across 4 states.
The verdict
NCT00002169, a Phase 2 study of HIV Infections and Cytomegalovirus Retinitis, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
Conditions Studied
Interventions
- DRUG Nelfinavir mesylate
Study Locations (8)
California
- Univ of Southern California / LA County USC Med Cntr - Los Angeles
- Univ of California / UCI Med Ctr - Orange
- Univ of California / San Diego Treatment Ctr - San Diego
- Harbor UCLA Med Ctr - Torrance
Texas
- Univ of Texas Med Branch - Galveston
- Baylor Univ - Houston
District of Columbia
- George Washington Univ - Washington D.C.
Illinois
- Northwestern Univ / SOCA - Chicago
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002169
The ClinicalTrials.gov registry entry for NCT00002169 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Agouron Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002169 reports 8 study locations spanning 4 distinct geographic areas - top geographies include California, Texas, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002169 about?
NCT00002169 is a clinical study titled "A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis". The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
What is the current status of trial NCT00002169?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00002169 study?
This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis.
What interventions are being tested in trial NCT00002169?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002169?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002169 being conducted?
This trial has 8 study locations across California, District of Columbia, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.